Ganga Pharmaceuticals Ltd
Ganga Pharmaceuticals: Net Profit at Rs. 186 Lakhs for Half Year Ended Sep 2026
RESULTS
▼ Concern Flagged
MEDIUM RISK
📅 Filed on BSE: 02 Nov 2026, 04:51 PM IST · BSE ID: 1bc7ad14-6890-4dc9-b36b-be56df1ac2e1
View Original BSE Filing (PDF)
💡
In Simple Terms
Ganga Pharmaceuticals reported Rs. 186 Lakhs in net profit from Rs. 14,163 Lakhs in revenue for the half year.
🤖 AI Summary
- Net Profit for Ganga Pharmaceuticals Ltd was Rs. 186 Lakhs for the half year ended September 30, 2026.
- Revenue from operations reached Rs. 14,163 Lakhs for the half year ended September 30, 2026.
- Total expenses amounted to Rs. 15,276 Lakhs for the half year ended September 30, 2026.
- Basic earnings per equity share stood at Rs. 0.03 for the half year ended September 30, 2026.
- The Board approved the unaudited financial results on November 02, 2026.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue from operations (Half year ended 30-09-2026)
14163 Lakhs
Revenue from operations (Half year ended 30-09-2025)
13665 Lakhs
Net Profit for the period (Half year ended 30-09-2026)
186 Lakhs
Net Profit for the period (Half year ended 30-09-2025)
550 Lakhs
Basic Earnings per equity share (Half year ended 30-09-2026)
0.03 Rs.
Basic Earnings per equity share (Half year ended 30-09-2025)
0.04 Rs.
Total Expenses (Half year ended 30-09-2026)
15276 Lakhs
🏢 How This Affects the Company
Revenue from operations for the half year ended September 30, 2026, was Rs. 14,163 Lakhs, which is an increase from Rs. 13,665 Lakhs in the comparable previous half year.
The company reported a Net Profit of Rs. 186 Lakhs for the half year ended September 30, 2026, compared to Rs. 550 Lakhs in the previous comparable half year. Long-term borrowings increased to Rs. 13.98 Lakhs as of September 30, 2026, from Rs. 9.81 Lakhs as of March 31, 2026.
The cost of materials consumed increased to Rs. 8,042 Lakhs for the half year ended September 30, 2026, from Rs. 7,004 Lakhs in the prior comparable period.
👥 What This Means For Shareholders
✅
Action Required
No immediate action required by shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the reported financial performance, specifically the decline in Net Profit to Rs. 186 Lakhs and Basic EPS to Rs. 0.03 for the half year ended September 30, 2026.
🔍
Management Signal
Management presented the half-yearly unaudited financial results, reflecting the company's performance for Q1 and Q2 of FY27.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q3 FY27 results — evaluate trends in net profit and revenue.
Next Board Meeting — observe any further financial or operational decisions.
Annual FY27 results — confirm full-year performance and outlook.
MEDIUM RISK
The significant decline in net profit despite revenue growth indicates potential margin pressures or increased costs.
💡 Investor Takeaway
Ganga Pharmaceuticals Ltd reported Net Profit of Rs. 186 Lakhs for the half year ended September 30, 2026 (Q2 FY27), a decrease from Rs. 550 Lakhs in the same period last year. Revenue from operations was Rs. 14,163 Lakhs, up from Rs. 13,665 Lakhs YoY.
⚖️ Strengths & Concerns
✅ Positives
- Revenue from operations increased by 3.64% to Rs. 14,163 Lakhs for the half year ended September 30, 2026, from Rs. 13,665 Lakhs in the prior comparable period.
- Employee Benefit Expenses decreased to Rs. 2,726 Lakhs for the half year ended September 30, 2026, from Rs. 3,197 Lakhs in the prior comparable period.
⚠️ Concerns
- Net Profit for the half year ended September 30, 2026, was Rs. 186 Lakhs, a decrease of 66.18% compared to Rs. 550 Lakhs in the previous comparable half year.
- Basic Earnings per Share (EPS) declined to Rs. 0.03 for the half year ended September 30, 2026, from Rs. 0.04 in the previous comparable half year.
📅 Company Track Record
No previous filings were found for Ganga Pharmaceuticals Ltd. The current filing provides the first publicly available unaudited financial results for the half year ended September 30, 2026, including comparable data for the half year ended September 30, 2025, and audited data for the year ended March 31, 2026.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Ganga Pharmaceuticals' Net Profit for the half year ended September 30, 2026?
Ganga Pharmaceuticals Ltd reported a Net Profit of Rs. 186 Lakhs for the half year ended September 30, 2026 (Q2 FY27).
What was the Revenue from Operations for Ganga Pharmaceuticals in the half year ended September 30, 2026?
Revenue from operations for Ganga Pharmaceuticals was Rs. 14,163 Lakhs for the half year ended September 30, 2026 (Q2 FY27).
How did Ganga Pharmaceuticals' Basic EPS change for the half year ended September 30, 2026?
Basic Earnings per Share (EPS) for Ganga Pharmaceuticals decreased to Rs. 0.03 for the half year ended September 30, 2026, from Rs. 0.04 in the comparable prior half year.
What were the total expenses for Ganga Pharmaceuticals for the half year ended September 30, 2026?
Total expenses for Ganga Pharmaceuticals Ltd amounted to Rs. 15,276 Lakhs for the half year ended September 30, 2026 (Q2 FY27).
Questions based on this BSE filing only. For information purposes.